Germany: German FPC adds another twist to pemetrexed case

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Germany: German FPC adds another twist to pemetrexed case

European patent EP 1 313 508 B1 claims the use of pemetrexed disodium in the manufacture of a medicament for use in a combination therapy together with vitamin B12 for inhibiting tumour growth. In the last six years, several courts throughout Europe have dealt with the question of whether medicaments containing a different salt or the free acid of pemetrexed infringe this patent by equivalent means. Most of the lower courts denied an infringement. However, the supreme courts went in a different direction: the UK Supreme Court (case no. [2017] UKSC 48, judgment of July 12 2017) and the Swiss Federal Supreme Court (case no. 4A_208/2017, judgment of October 20 2017) found infringement under the doctrine of equivalence. The decision of the German Federal Supreme Court (case no. X ZR 29/15, judgment of June 14 2016) was only concerned with one aspect of the doctrine. However, in light of this decision, the German Higher Regional Court of Munich confirmed infringement by equivalent means in its judgment of May 18 2017 (case no. 6 U 3039/16).

In contrast to the numerous infringement proceedings, national court decisions regarding the validity of European patent EP 1 313 508 B1 – which was maintained as granted in the opposition proceedings before the European Patent Office – are rare. In the UK and Swiss proceedings mentioned above, validity was not challenged. Validity was challenged in Germany, but not in the above-mentioned proceedings. Due to the so-called bifurcated system, validity of a patent and patent infringement cannot be dealt with in the same proceedings in Germany. Lack of validity has to be raised in separate proceedings before the German Federal Patent Court (FPC). In July 2018, the FPC revoked the German part of EP 1 313 508 B1 (case no. 3 Ni 23/16 (EP), judgment of July 17 2018). The reasons for this decision were published in November 2018. According to the FPC, the combined use of pemetrexed disodium and vitamin B12 for inhibiting tumour growth is obvious in view of the prior art.

Presently, an appeal is pending before the German Federal Supreme Court. It remains to be seen whether the Federal Supreme Court will confirm the decision of the FPC or add still another twist to the pemetrexed case. Overall, the pemetrexed case with all its twists is reminiscent of a quote attributed to the baseball legend Lawrence Peter "Yogi" Berra: "It ain't over till it's over."

renate-rieder.jpg

Renate Rieder

Maiwald Patentanwalts- und Rechtsanwalts GmbH

Elisenhof, Elisenstr 3

D-80335, Munich, Germany

Tel: +49 89 74 72 660 

Fax: +49 89 77 64 24

info@maiwald.eu

www.maiwald.eu

more from across site and SHARED ros bottom lb

More from across our site

Six hires across the IP spectrum reflect Orrick’s efforts to better serve tech clients across the IP lifecycle
David Stone, partner at White & Case, argues that the government’s planned reforms will modernise and futureproof UK design law, but leave two of the thorniest problems unresolved
Max Scott will join the firm’s IP transactions group in California, becoming the latest Weil IP partner to secure their future
Yonatan Drori, attorney at Drori-Stav IP in Israel, explains why foreign counsel must treat Israel’s patent disclosure requirements as an ongoing obligation, rather than a one-off formality
From Japan to Southeast Asia, domestic and regional firms picked up some of the biggest prizes, while key foreign players maintained momentum
Earlier this month, Managing IP had exclusively reported that the French arm of Taylor Wessing was minded to pull out of the deal
Our latest podcast examines how Weil’s IP practice evolved, where its practitioners could (and will) go next, and which firms and markets stand to benefit from the redistribution of talent
Former Latham partner Chris Henry and transactions lawyer Liza Cotter are heading to the firm as Weil’s IP practice starts to disperse
Rival IP teams return to court for a closely watched appeal over AI and copyright, but observers hoping for answers to some of the technology’s biggest legal questions may be left disappointed
Eight years after its launch, members of the Australian patent firm’s Singapore office explain its growth strategy over the past year
Gift this article